Cellcura ASA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Cellcura ASA Proposes Directed Share Issue
Cellcura ASA announced that the Board of Directors of the Company has proposed to conduct a directed share issue towards selected investors and shareholders as well as a repair issue towards those investors/shareholders, who didn't take part in directed share issue. The maximum increase of the share capital is NOK 25,000,000 and the maximum number of shares that may be issued is 250,000,000 in each of the proposed share issue resolutions. The issue is subject to Extraordinary General Meeting's (EGM's) approval. The EGM is scheduled for June 6, 2013.
Latest Developments for Cellcura ASA
Latest Key Developments in Medical
- Cardiovascular Systems Inc receives FDA clearance for low profile, 60cm diamondback devices designed to expand the treatment of peripheral artery disease
- BenQ Medical Technology Corp announces FY 2013 dividend payment
- Visgeneer Inc announces FY 2013 dividend payment
- Hill-Rom Holdings Inc announces 11 pct dividend increase in second quarter 2014
- Share this
- Digg this